Details 3 Related Guidelines / Approvals

Indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).

type

FDA Approval

approval date

2021-10-29

settings
settings
Chronic phase
settings
Subsequent line
source

FDA